Matthias Mann

Research director, professor


The Mann group - Clinical Proteomics will undertake an ambitious new biomedical research programme involving proteomics of blood/plasma for patient phenotyping. The aim is to identify biological markers for diabetes, obesity and other metabolic disorders that can be used to improve diagnosis and develop more individualized therapies.

The group will build on its world leading expertise in proteomics technologies and implement a high sensitivity and high accuracy platform to analyze the proteomics of up to 100 individuals per day at great accuracy and depth of coverage.

Together with partners at Steno Diabetes Center, Rigshospitalet, Panum Institute, the Novo Nordisk Foundation Center for Basic Metabolic Research at the University of Copenhagen and elsewhere, they will apply this platform to characterize the blood proteome and how it is associated with known and novel metabolic risk factors for diabetes and cardiovascular disease.

© All rights reserved, Sciencenews 2020